Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products: • with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; • when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
Thiotepa is indicated, in combination with other chemotherapy medicinal products: • with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients; • when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.